Subject index of volume 113

Abuse potential 381
Accumbens 103
Acetylcholine 119
Acoustic startle response 487
Active coping 37
Activity 205, 211, 429
Acute and chronic treatments 463
Acute tolerance 304
Adenosine triphosphate (ATP)-sensitive potassium channel 318
Adenosine triphosphate (ATP)-sensitive potassium (K_{ATP}) channel 11
Adrenalectomy 481
β-Adrenergic antagonist 119
β-Adrenergic receptor 539
β adrenergic receptors 1
α_2-Adrenoceptor antagonists 527
AF102B 361
Ageing 274
Albuterol 243
Alcohol 26, 269, 346
Alcohol-preferring and -nonpreferring rats 60
Alpha-adrenoceptors 493
Alpha-ethyltryptamine 284
Alpidem 395
Amnesia 311
Amphetamine 110, 217
Amygdala 123
Analgesia 534
Antidepressant 1, 76
Antidepressant drugs 89, 243
Antidepressants 225
Antinociception 11, 167, 318
Anxiety 137, 237, 262, 351, 463, 543
Anxiolytic 211, 395
Anxiolytic effect 565
Apomorphine hypermotility 555
Apomorphine stereotypy 555
Atenolol 131
Attention 304
Aversive brain stimulation 565
Avoidance behaviour 217
A 68930 45

Barbital 521
Behavior 177, 187, 328, 351
Behavioral sensitization 404
Behavioral tolerance 269
Behaviour 172, 471
Behavioural development 388
Benzodiazepine 311
Benzodiazepines 351, 395
Benztropine 119
Beta adrenergic receptors 89, 243
Beta-adrenergic antagonists 131
Blood glucose 83
Body height 222
Brain concentrations 199
Brain metabolism 53
Bremazocine 457
Burying behavior 211
BW 737C 45

Caffeine 411, 438
Calcium 322
Calcium antagonists 378
Calcium channel 555
Calcium channel antagonists 521
Cardiovascular 37
Cardiovascular effects 438
Cat odour 543
Catalepsy 257
Cataplexy 76
Cerebral cortex 539
CHA 257
Chaos 95
Chlordiazepoxide 211
Chlordiazepoxide hydrochloride 570
Cholinergic manipulations 157
Chronic cocaine 547
Cianopramine 463
Cigarette 95
Citalopram 225, 463
Classical conditioning 123, 404
Clomipramine 53
Clozapine 250
Cluster analysis 500
Cocaethylene 144
Cocaine 67, 123, 131, 144, 378, 404, 518
Cognition 361
Computer modeling 339
Conditioned aversion 422
Conditioned defensive burying 131, 211
Conditioned locomotion 123, 404
Conditioned place preference 31, 123
Conditioned reward 110
Continuous processes 289
Corticosterone 481, 543, 547
Cortisol 334, 561
Cromakalim 318
CSF 222
CSF/plasma ratio 222
Cynomolgus monkey 149

DAMGO 167
Dementia 361
Depression 222, 225, 322
Development 422
Diabetes 167, 318
Diazepam 304, 339
Diazepam response 237
Diphenylhydantoin 471
Discrimination 205
Distress vocalization 422
DMCM 351
DOI 274, 429
Dopamine 51, 76, 103, 110, 328, 378, 453, 487, 518
Dopamine agonist 518
Dopamine antagonist 199
Dopamine D-1 and D-2 receptors 45
Dopamine D_1 antagonist 250
Dopamine D_2 antagonist 250
Dopamine receptors 476
Dopamine releasers 187
Dopamine uptake inhibitors 187
Dorsal periaqueductal grey 565
Dorsal raphe 31, 481
[D-Pen^{2,5}]enkephalin 318
DRL 72-S schedule 1
Drug Discrimination 26, 289, 351, 395
Drug interaction 346
Drug-drug discrimination 289
D-1:D-2 interactions 45
D_1 328
D_1 dopamine receptor 199
D_1 receptors 51, 110, 157
D_1 supersensitivity 157
D_1-dopamine receptors 149
D_2 receptors 110, 157, 172

Early social interactions 388
EEG 95, 471
EEG spectral analysis 60
Electroconvulsive shock 555
Electrocortical 37
Elevated plus maze 570
Elevated plus-maze 237, 565
Elevated plus-maze test 463
Endocrine 547
Environment-dependent ethanol tolerance 511
Environment-independent ethanol tolerance 511
Ephedrine 381
Ethanol 26, 231, 453
Ethanol self-administration 60
Ethogram 500
Ethopharmacology 500
Excitatory amino acids 565

Feeding 262, 328, 369
Flumazenil 211, 334, 351
Flunitrazepam 304
Fluoxetine 284
β-FNA 457
Foraging 231
Forced swimming stress 15
Fowles' interpretation 137

Gender 381
Generalization 289
Gestational barbiturate exposure 388
Glibenclamide 318
Glutamate 453
Gray's model 137
Grooming 45
Growth hormone 334, 561

Habituation 543, 570
Hallucinogen 429
Haloperidol 19, 103, 404
Haloperidol (intermittent) 157
Hippocampus 481, 539
Hot plate 500
5-HT agonist induced behaviours 274
5-HT receptor 561
5-HT reuptake inhibitors 463
5-HT uptake sites 481
5-HT_2 receptors 369
5-HT_2 328, 429
5-HT_{1A} receptor 481
5-HT_{1A} 429
5-HT_{1B} 369
5-HT_{1C} receptor 262
5-HT_{1C} 328, 369
Human 149, 346
Human brain 311
Humans 83, 144, 269, 381
6-Hydroxydopamine 487
5-Hydroxytryptamine 31, 274
8-Hydroxy-2-(din-propyl)aminotetralin 539
Hypothermia 539

Idazoxan 172, 493
Imidazoline 493
Impairment of acquisition 339
Inbred mice 388
Individual differences 381
Information 269
Inhibitory avoidance 476
Inverse agonists 351
IRT analysis 1
Isradipine 378

Kappa opioids 457
[^{3}H] Ketanserin binding 274

Learning 511
Light/dark box 237
Light/dark choice procedure 463
l-Methadone 457
Locomotion 262, 284, 429, 453
Locomotor activity 89, 243, 445
LSD 429
L-type Ca^{2+} channels 404
L-689,660 361

Major tranquilizers 250
Marijuana 346
m-Chlorophenylpiperazine 262
MDMA 284
Median raphe 31
Memory 83, 311, 476
Mental performance 37
Methysergide 1
Metoclopramide 110
Metoprolol 1
Mice 167, 217, 237, 257, 361, 476
Microstructure 177, 187
Midazolam 334
Milk drinking 67
Minaprine 476
MK-801 (dizocilpine) 453
Monase 284
Mood 381, 411
Morphine 11, 167, 318, 445, 457, 500
Morphine abstinence 555
Morphine dependence 131
Mouse 11, 15, 453
Mu opioids 457
Muscarinic acetylcholine receptors 311
Muscarinic receptor agonists 361
M_1, M_3 361

Naloxone 500
Naloxone-induced antinociception 527
Naltrexone 457
Naltrindole 15, 167
Narcolepsy 76
NECA 257
Neophobia 463
Neural interactions 311
Neuroleptic drugs 119
Nicotine 205, 438, 445, 534
Nifedipine 217, 555
Nimodipine 404
Nitrous oxide 211
NMDA 471
NMDA receptor 565
N-Methyl-D-aspartate receptor 511
NMPB 311
NNC 687 149
NNC-756 45, 149
Nonlinear dynamics 95
Noradrenaline 76
Norepinephrine 493
NT 222
N1 411

8-OH-DPAT 31, 274, 429
1-OH-NT 222
One-trial tolerance 570
Ontogeny 422
Operant 1
Operant behavior 89, 243
Opiate 527
Opiates 422
Opioid antagonism 457
δ-Opioid receptor 15, 167
Opioid tolerance 457
κ Opioids 422
Oxazepam 137

P and NP rats 60
Pain 527
Partial agonist 518
Passive coping 37
Penile erection 172
PET 311
Phenobarbitone 388
Physical activity 438
Pimozide 110
Place preference conditioning 445
Plasma concentrations 199
Platelet 322
Play 493
Plus-maze 543
Polysomnography 225
Positron emission tomography 149
Prazosin 493
Prefrontal cortex 487
Prenatal 534
Prepulse inhibition 487
Prior experience 237
Procurement 231
Prolactin 547, 561
Propranolol 119, 131
Psychomotor performance 304
8PT 257
Purinergic drugs 521
P3 411

Quantal processes 289
Quantified smoke delivery system 95
Quinpirole 19, 103

Raclopride 250
Rapid information processing task 37
Rat 45, 177, 187, 205, 250, 328, 369, 378, 487, 534
Rate-decreasing effects 457
Rats 26, 53, 67, 157, 211, 231, 284, 361, 429, 445
Reaction times 411
α_2 receptors 172
REM sleep 76
Renin 547
Retest 237
Reward 110
R-PIA 257
RU 24213 172
RX821002 493

Salbutamol 1
Saliva caffeine concentrations 411
Satiety sequence 369
Scaling measures 177
Schedule-controlled responding 19, 457
Schedule-induced polydipsia 250
Schedules of reinforcement 289
Schizophrenia 487
SCH 23390 19, 45, 110, 250, 328, 476
SCH 39166 199, 328
Search 231
Self-administration 51, 231, 346, 378, 381
Sensitization (pharmacological) 157
Sensorimotor 103
Serotonin 26, 53, 76, 284, 322, 429, 481
Serotonin receptor antagonists 527
Serotonin receptors 1
Serotonin-1A receptor 539
Serotonin-2 receptor 539
Sertraline 262
SIP 250
SKF 38393 19
SKF 38393 328
SKF 82958 328
Sleep EEG 334
Smokers 438
SND 919 172
Spinal noradrenaline turnover 11
Spiperone 19
Squirrel monkeys 19
Startle 103, 205
State of the subject 411
Stereotypy 172
Stimulus degradation 411
Stimulus-response compatibility 411
Stress 37, 547
Stress induced antinociception 15
Stretching-yawning 172
Strychnine-insensitive glycine receptor antagonists 565
St 587 493
Subjective and cardiovascular effects 144
Subjective effects 346, 381, 438
Substance abuse 123
(−)Sulpiride 476
Sumatriptan 561

Tardive akathisia 119
Tardive dyskinesia 157
TFMPP 26
Theophylline 257
Time uncertainty 411
Tolerance 67, 429, 521
Triazolam 311

Ultrasonic vocalization 422
Uptake inhibition 76
U50,488 422, 457
U69,593 457

Vacuous chewing 45
Vacuous chewing movements 157
Valproate 539
Visual event-related potentials 411

Withdrawal 131, 205
Withdrawal syndrome 521

Yohimbine 172

Zinterol 89
Zolpidem 395